Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
10510 studies found for:    NCI
Show Display Options
Rank Status Study
1 Active, not recruiting Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
Conditions: Adenocarcinoma of the Prostate;   Stage II Prostate Cancer
Interventions: Drug: finasteride;   Other: placebo;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
2 Unknown  Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma
Conditions: Cardiac Toxicity;   Sarcoma
Interventions: Biological: filgrastim;   Drug: cisplatin;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: methotrexate;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy
3 Completed ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: fluorouracil;   Drug: gefitinib;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
4 Completed
Has Results
Bortezomib in Treating Patients With Lymphoproliferative Disorders
Conditions: Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma
Intervention: Drug: bortezomib
5 Completed Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: sorafenib tosylate;   Drug: erlotinib hydrochloride;   Drug: tipifarnib;   Drug: temsirolimus
6 Active, not recruiting Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Condition: Malignant Neoplasm
Interventions: Drug: Vismodegib;   Other: Pharmacological Study
7 Completed Vaccine Therapy in Treating Patients With Metastatic Cancer
Conditions: Melanoma (Skin);   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: aldesleukin;   Biological: incomplete Freund's adjuvant;   Biological: telomerase: 540-548 peptide vaccine
8 Completed
Has Results
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Drug: temozolomide;   Drug: motexafin gadolinium
9 Active, not recruiting AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Cerebral Anaplastic Astrocytoma;   Childhood Cerebral Astrocytoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood Infratentorial Ependymoma;   Childhood Oligodendroglioma;   Childhood Spinal Cord Neoplasm;   Childhood Supratentorial Ependymoma;   Recurrent Childhood Brain Neoplasm;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway Glioma
Intervention: Drug: Cediranib Maleate
10 Completed
Has Results
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
Condition: Recurrent Endometrial Carcinoma
Interventions: Biological: bevacizumab;   Other: laboratory biomarker analysis
11 Recruiting Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
Conditions: Adult Solid Neoplasm;   Recurrent Colon Carcinoma;   Recurrent Rectal Carcinoma;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: Selumetinib;   Drug: Cyclosporine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
12 Completed Oxaliplatin in Treating Patients With Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: oxaliplatin;   Other: laboratory biomarker analysis
13 Completed Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Conditions: Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: omacetaxine mepesuccinate;   Other: pharmacological study;   Other: laboratory biomarker analysis
14 Active, not recruiting RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: vismodegib;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: pharmacogenomic studies
15 Completed Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: atrasentan hydrochloride
16 Completed PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
Conditions: Adult Acute Promyelocytic Leukemia (M3);   Blastic Phase Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia
Intervention: Drug: bortezomib
17 Active, not recruiting Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: Vorinostat;   Drug: Bortezomib;   Other: Laboratory Biomarker Analysis
18 Completed 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sorafenib tosylate;   Drug: tanespimycin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: magnetic resonance imaging
19 Completed BMS-247550 in Treating Patients With Stage IV Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: ixabepilone;   Other: pharmacogenomic studies;   Other: laboratory biomarker analysis
20 Terminated RO4929097 in Treating Patients With Recurrent Invasive Gliomas
Conditions: Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Recurrent Adult Brain Tumor
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years